| Literature DB >> 28221367 |
N Lopizzo1, S Tosato2, V Begni3, S Tomassi2, N Cattane1, M Barcella2, G Turco2, M Ruggeri2, M A Riva3, C M Pariante4, A Cattaneo1,4.
Abstract
Stressful life events occurring in adulthood have been found able to affect mood and behavior, thus increasing the vulnerability for several stress-related psychiatric disorders. However, although there is plenty of clinical data supporting an association between stressful life events in adulthood and an enhanced vulnerability for psychopathology, the underlying molecular mechanisms are still poorly investigated. Thus, in this study we performed peripheral/whole-genome transcriptomic analyses in blood samples obtained from 53 adult subjects characterized for recent stressful life events occurred within the previous 6 months. Transcriptomic data were analyzed using Partek Genomics Suite; pathway and network analyses were performed using Ingenuity Pathway Analysis and GeneMANIA Software. We found 207 genes significantly differentially expressed in adult subjects who reported recent stressful life experiences (n=21) compared with those without such experiences (n=32). Moreover, the same subjects exposed to such stressful experiences showed a reduction in leukocyte telomere length. A correlation analyses between telomere length and transcriptomic data indicated an association between the exposures to recent stressful life events and the modulation of several pathways, mainly involved in immune-inflammatory-related processes and oxidative stress, such as natural killer cell signaling, interleukin-1 (IL-1) signaling, MIF regulation of innate immunity and IL-6 signaling. Our data suggest an association between exposures to recent stressful life events in adulthood and alterations in the immune, inflammatory and oxidative stress pathways, which could be also involved in the negative effect of stressful life events on leukocyte telomere length. The modulation of these mechanisms may underlie the clinical association between the exposure to recent Stressful life events in adulthood and an enhanced vulnerability to develop psychiatric diseases in adulthood.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28221367 PMCID: PMC5438034 DOI: 10.1038/tp.2017.5
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Top significantly modulated genes by SLEs exposure
| 1 | CD38 molecule | −1.4 | |
| 2 | Ring finger protein 182 | −1.4 | |
| 3 | SLAM family member 7 | −1.4 | |
| 4 | Perforin-1 (pore forming protein) | −1.4 | |
| 5 | SH2 domain containing 1B | −1.4 | |
| 6 | Immunoglobulin heavy variable 3–33 | −1.3 | |
| 7 | Immunoglobulin lambda joining 3 | −1.3 | |
| 8 | Immunoglobulin heavy variable 3–38 | −1.3 | |
| 9 | Fc receptor-like 5 | −1.3 | |
| 10 | Histone cluster 1, H3i | −1.3 | |
| 11 | G-protein-coupled receptor 56 | −1.3 | |
| 12 | Transforming growth factor, beta receptor III | −1.3 | |
| 13 | S100 calcium binding protein A9 | 1.2 | |
| 14 | Cystatin A (stefin A) | 1.2 | |
| 15 | Carboxymethylenebutenolidase homolog | 1.2 | |
| 16 | Ribosomal protein S26 | 1.2 | |
| 17 | RNA, 5S ribosomal 399 | 1.3 | |
| 18 | Ribosomal protein L7 | 1.3 | |
| 19 | Interleukin 8 | 1.3 | |
| 20 | Tubulin, beta 4B class Ivb | 1.3 | |
| 21 | Lymphocyte antigen 96 | 1.3 | |
| 22 | Ribosomal protein L21 | 1.3 | |
| 23 | S100 calcium binding protein A8 | 1.4 | |
| 24 | KIAA1324 | 1.6 |
Abbreviation: SLE, stressful life event.
Selection of the 24 genes with the lowest or highest values of fold change (all q-value<0.05), 12 downregulated and 12 upregulated.
Pathways differentially modulated in subjects exposed to SLEs (P-value<0.05)
| 1 | Role of IL-17A in psoriasis | CXCL8, S100A9, S100A8, CXCL1 |
| 2 | Caveolar-mediated endocytosis signaling | FLNB, FLNA, ABL1, ITGAL, ITGB7 |
| 3 | Natural killer cell signaling | CD247, NCR1, LAT, ZAP70, KIR3DL2, SH2D1B |
| 4 | Tumoricidal function of hepatic natural killer cells | PRF1, GZMB, ITGAL |
| 5 | Virus entry via endocytic pathways | FLNB, FLNA, ABL1, ITGAL, ITGB7 |
| 6 | Cytotoxic T lymphocyte-mediated apoptosis of target cells | CD247, PRF1, GZMB |
| 7 | Superpathway of methionine degradation | FTSJ1, GOT2, AHCY |
| 8 | Role of IL-17F in allergic inflammatory airway diseases | CXCL8, CCL4, CXCL1 |
| 9 | CTLA4 signaling in cytotoxic T lymphocytes | CD247, PPP2R5D, LAT, ZAP70 |
| 10 | Granzyme B signaling | PRF1, GZMB |
| 11 | Crosstalk between dendritic cells and natural killer cells | PRF1, KIR3DL2, ITGAL, IL2RB |
| 12 | Methionine degradation I (to Homocysteine) | FTSJ1, AHCY |
| 13 | Differential regulation of cytokine production in macrophages and T helper cells by IL-17A and IL-17F | CCL4, CXCL1 |
| 14 | T-cell receptor signaling | CD247, PTPRH, LAT, ZAP70 |
| 15 | Cysteine biosynthesis III (mammalia) | FTSJ1, AHCY |
| 16 | Granzyme A signaling | PRF1, HIST1H1E |
| 17 | iCOS-iCOSL signaling in T helper cells | CD247, LAT, ZAP70, IL2RB |
| 18 | Glycine biosynthesis I | SHMT2 |
| 19 | Differential regulation of cytokine production in intestinal epithelial cells by IL-17A and IL-17F | CCL4, CXCL1 |
| 20 | TCA cycle II (eukaryotic) | SDHA, ACO1 |
| 21 | IL-17A signaling in gastric cells | CXCL8, CXCL1 |
| 22 | Cell cycle control of chromosomal replication | MCM3, CDK6 |
| 23 | NADH repair | APOA1BP |
| 24 | 5-aminoimidazole ribonucleotide biosynthesis I | GART |
| 25 | Glutamate degradation II and aspartate biosynthesis | GOT2 |
| 26 | Aspartate biosynthesis | GOT2 |
| 27 | EIF2 signaling | RPS26, RPL21, RPS21, RPL7, RPSA |
| 28 | TREM1 signaling | SIGIRR, CXCL8, NLRC3 |
| 29 | Cyclins and cell cycle regulation | PPP2R5D, CDK6, ABL1 |
| 30 | Proline biosynthesis I | ALDH18A1 |
| 31 | GOT2 | |
| 32 | Phenylalanine degradation I (Aerobic) | QDPR |
| 33 | Regulation of IL-2 expression in T lymphocytes | CD247, LAT, ZAP70 |
| 34 | Ceramide signaling | SMPD4, S1PR5, PPP2R5D |
| 35 | Tetrahydrofolate salvage from 5,10-methenyltetrahydrofolate | GART |
| 36 | dTMP | SHMT2 |
| 37 | Folate polyglutamylation | SHMT2 |
| 38 | Regulation of eIF4 and p70S6K signaling | RPS26, PPP2R5D, RPS21, RPSA |
Abbreviations: IL, interleukin; SLE, stressful life event.
All the 38 pathways obtained from Ingenuity pathway analysis (P-value<0.05) using as input gene set all the 207 genes significantly modulated in subjects exposed to SLEs.
Figure 1Network of genes significantly modulated and their main pathways. Gene network shows the relationships between genes from the input gene list (30 striped nodes in black) and genes strictly related from literature (small nodes in black) connected (with edges) according to the functional association networks from the databases. Different lines and colors denote the different type of interactions: in purple co-expression, in orange predicted, in blue co-localization, in green genetic interactions, in light red physical interactions, in light blue pathway.
Pathways significantly correlated with telomere shortening in association with SLEs exposures
| 1 | Natural killer cell signaling | KIR3DL1, RRAS2, LAIR1, INPP5B, SYK, MAPK3, KIR3DL2, KIR2DL4, KIR3DL3 |
| 2 | Phosphatidylglycerol biosynthesis II | GPAM, LPCAT4, PTPMT1, AGPAT1 |
| 3 | Prostate cancer signaling | RRAS2, FOXO1, PA2G4, MAPK3, NFKBIE, NFKB2, GSTP1 |
| 4 | Ephrin B signaling | GNAS, RGS3, MAPK3, GNAO1, ACP1, HNRNPK |
| 5 | CDP-diacylglycerol biosynthesis I | GPAM, LPCAT4, AGPAT1 |
| 6 | MIF-mediated glucocorticoid regulation | MAPK3, NFKBIE, CD14, NFKB2 |
| 7 | Triacylglycerol biosynthesis | GPAM, LPCAT4, AGPAT1, PLPP1 |
| 8 | Role of NFAT in regulation of the immune response | GNAS, RRAS2, SYK, MAPK3, NFKBIE, GNAO1, MS4A2, MEF2A, NFKB2 |
| 9 | Crosstalk between dendritic cells and natural killer cells | KIR3DL1, FSCN1, KIR3DL2, NFKB2, KIR2DL4, KIR3DL3 |
| 10 | IL-1 signaling | IL1A, GNAS, NFKBIE, GNAO1, NFKB2, IRAK2 |
| 11 | MIF regulation of innate immunity | MAPK3, NFKBIE, CD14, NFKB2 |
| 12 | iNOS signaling | NFKBIE, CD14, NFKB2, IRAK2 |
| 13 | LPS-stimulated MAPK signaling | RRAS2, MAPK3, NFKBIE, CD14, NFKB2 |
| 14 | D-myo-inositol (1,4,5)-trisphosphate biosynthesis | PIP4K2B, PI4K2B, PLCH1 |
| 15 | TNFR1 signaling | NAIP, CRADD, NFKBIE, NFKB2 |
| 16 | PDGF signaling | RRAS2, ABL2, INPP5B, MAPK3, ACP1 |
| 17 | fMLP signaling in neutrophils | ACTR2, GNAS, RRAS2, MAPK3, NFKBIE, NFKB2 |
| 18 | Ephrin receptor signaling | ACTR2, GNAS, RGS3, RRAS2, PTPN13, MAPK3, GNAO1, ACP1 |
| 19 | TNFR2 signaling | NAIP, NFKBIE, NFKB2 |
| 20 | Glutathione-mediated detoxification | HPGDS, ANPEP, GSTP1 |
| 21 | PPARα/RXRα activation | GNAS, RRAS2, PRKAB1, MAPK3, NFKBIE, CYP2C18, NFKB2, ACVR1C |
| 22 | Epithelial adherens junction signaling | EPN2, ACTR2, RRAS2, LMO7, TUBB4A, ACVR1C, FARP2 |
| 23 | Histamine biosynthesis | HDC |
| 24 | Alanine biosynthesis III | NFS1 |
| 25 | 4-1BB signaling in T lymphocytes | MAPK3, NFKBIE, NFKB2 |
| 26 | IL-6 signaling | IL1A, RRAS2, MAPK3, NFKBIE, CD14, NFKB2 |
| 27 | Choline biosynthesis III | PLD3, PHKA1 |
| 28 | Apoptosis signaling | NAIP, RRAS2, MAPK3, NFKBIE, NFKB2 |
| 29 | TWEAK signaling | NAIP, NFKBIE, NFKB2 |
| 30 | PI3K/AKT signaling | RRAS2, FOXO1, INPP5B, MAPK3, NFKBIE, NFKB2 |
| 31 | IL-17A signaling in fibroblasts | MAPK3, NFKBIE, NFKB2 |
| 32 | PPAR signaling | IL1A, RRAS2, MAPK3, NFKBIE, NFKB2 |
| 33 | Superpathway of inositol phosphate compounds | ATP1A1, PTPN13, NUDT9, INPP5B, PIP4K2B, ACP1, PI4K2B, PLCH1 |
| 34 | IL-15 signaling | RRAS2, SYK, MAPK3, NFKB2 |
| 35 | Role of PI3K/AKT signaling in the pathogenesis of influenza | IFNA8, MAPK3, NFKBIE, NFKB2 |
| 36 | Hepatic cholestasis | IL1A, GNAS, ABCC2, NFKBIE, CD14, NFKB2, IRAK2 |
| 37 | Eicosanoid signaling | PTGFR, DPEP3, ALOX5AP, HPGDS |
| 38 | Phospholipase C signaling | ARHGEF5, GNAS, PLD3, RRAS2, SYK, MAPK3, MEF2A, NFKB2, RHOH |
| 39 | Angiopoietin signaling | RRAS2, FOXO1, NFKBIE, NFKB2 |
| 40 | Erythropoietin signaling | RRAS2, MAPK3, NFKBIE, NFKB2 |
| 41 | Insulin receptor signaling | RRAS2, FOXO1, TRIP10, INPP5B, MAPK3, ASIC3 |
| 42 | Antioxidant action of vitamin C | PLD3, MAPK3, NFKBIE, NFKB2, SLC2A3 |
| 43 | IL-10 signaling | IL1A, NFKBIE, CD14, NFKB2 |
| 44 | Spermine biosynthesis | SMS |
| 45 | Cardiolipin biosynthesis II | PTPMT1 |
| 46 | Putrescine biosynthesis III | AZIN2 |
| 47 | Cholecystokinin/gastrin-mediated signaling | IL1A, RRAS2, MAPK3, MEF2A, RHOH |
| 48 | Small cell lung cancer signaling | PA2G4, NFKBIE, NFKB2, SKP2 |
| 49 | PEDF signaling | RRAS2, MAPK3, NFKBIE, NFKB2 |
| 50 | B-cell receptor signaling | RRAS2, FOXO1, INPP5B, SYK, MAPK3, NFKBIE, NFKB2 |
| 51 | Rac signaling | ACTR2, RRAS2, MAPK3, PIP4K2B, NFKB2 |
| 52 | Role of RIG1-like receptors in antiviral innate immunity | IFNA8, NFKBIE, NFKB2 |
| 53 | Systemic lupus erythematosus signaling | IL1A, RRAS2, IFNA8, PRPF3, MAPK3, SNRPB2, PRPF6, SNRPE |
| 54 | NF-KB activation by viruses | RRAS2, MAPK3, NFKBIE, NFKB2 |
| 55 | Toll-like receptor signaling | IL1A, CD14, NFKB2, IRAK2 |
| 56 | Fc epsilon RI signaling | RRAS2, INPP5B, SYK, MAPK3, MS4A2 |
Abbreviations: IL, interleukin; SLE, stressful life events. All the 56 pathways from Ingenuity pathway analysis, using as input gene set the 405 genes significantly correlated between telomere shortening and SLEs (P-value<0.05).
Figure 2Biological processes pie chart. Pathways related both to SLEs and telomere shortening grouped according to their associated biological processes. SLE, stressful life events.